Peter Rasmussen - Ascendis Pharma Principal Accounting Officer and VP of Fin.
| ASND Stock | USD 224.19 2.16 0.97% |
VP
Mr. Peter Rasmussen was Vice President, Finance and Principal Financial and Accounting Officer of Ascendis Pharma AS since February 2016. He was Principal Accounting Officer, Vice President Finance at the Company since March 2014. Prior to joining Ascendis Pharma, Mr. Rasmussen worked as a financial consultant for Ascendis Pharma from October 2013 to March 2014. From June 2008 to August 2012, Mr. Rasmussen served as the Chief Financial Officer of AdvanDx, Inc., a privately held medical device company. From 2007 to 2008, prior to AdvanDx, Mr. Rasmussen served as Head of Finance at Veloxis Pharmaceuticals AS. Mr. Rasmussen is a stateauthorized public accountant in Denmark and received an M.Sc. in Business Economics and Auditing from Copenhagen Business School. since 2016.
| Age | 55 |
| Tenure | 10 years |
| Address | Tuborg Boulevard 12, Hellerup, Denmark, 2900 |
| Phone | 45 70 22 22 44 |
| Web | https://ascendispharma.com |
Ascendis Pharma Management Efficiency
The company has return on total asset (ROA) of (0.0769) % which means that it has lost $0.0769 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.1843) %, meaning that it created substantial loss on money invested by shareholders. Ascendis Pharma's management efficiency ratios could be used to measure how well Ascendis Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 3.38, whereas Return On Tangible Assets are forecasted to decline to (0.39). At present, Ascendis Pharma's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 47.6 M, whereas Intangible Assets are forecasted to decline to about 455.7 K.Similar Executives
| Found 11 records | VP Age | ||
| Rashmi Ramchandani | Biomarin Pharmaceutical | 47 | |
| Brian Mueller | Biomarin Pharmaceutical | 50 | |
| Sanjay MD | Ionis Pharmaceuticals | N/A | |
| George JD | Biomarin Pharmaceutical | 55 | |
| Jeff JD | Revolution Medicines | 50 | |
| George Davis | Biomarin Pharmaceutical | 53 | |
| Laura Woodhead | Biomarin Pharmaceutical | 57 | |
| Stefan Krauss | Exelixis | N/A | |
| Sujit Basu | Ionis Pharmaceuticals | N/A | |
| Eugene MD | Ionis Pharmaceuticals | 52 | |
| Brinda MD | Biomarin Pharmaceutical | 44 | |
Management Performance
| Return On Equity | -8.18 | ||||
| Return On Asset | -0.0769 |
Ascendis Pharma AS Leadership Team
Elected by the shareholders, the Ascendis Pharma's board of directors comprises two types of representatives: Ascendis Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ascendis. The board's role is to monitor Ascendis Pharma's management team and ensure that shareholders' interests are well served. Ascendis Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ascendis Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael LLM, Chief VP | ||
| Birgitte MD, Sr Affairs | ||
| Stina MD, Executive Oncology | ||
| Scott Holmes, Head Endocrinology | ||
| Timothy Lee, Director Relations | ||
| Jay Wu, Executive US | ||
| Nyssa Noyola, Vice Management | ||
| Jens Okkels, VP Devel | ||
| Flemming Jensen, Senior Vice President Product Supply | ||
| Pedersen Sonderbjerg, Chief VP | ||
| Scott Smith, CFO, Senior Vice President | ||
| Mads Bodenhoff, Senior Officer | ||
| Jan Mikkelsen, CEO and President Member of Executive Board and Executive Director | ||
| Joseph Kelly, Head Endocrinology | ||
| Chad Fugure, Vice Relations | ||
| Lotte Sonderbjerg, Sr Officer | ||
| Peter Rasmussen, Principal Accounting Officer and VP of Fin. | ||
| Kennett Sprogoe, Executive Development | ||
| Sherrie Glass, Chief Officer |
Ascendis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ascendis Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -8.18 | ||||
| Return On Asset | -0.0769 | ||||
| Profit Margin | (0.36) % | ||||
| Operating Margin | 0.05 % | ||||
| Current Valuation | 13.91 B | ||||
| Shares Outstanding | 61.1 M | ||||
| Shares Owned By Insiders | 0.75 % | ||||
| Shares Owned By Institutions | 99.25 % | ||||
| Number Of Shares Shorted | 3.16 M | ||||
| Price To Earning | (9.10) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Will Biotechnology sector continue expanding? Could Ascendis diversify its offerings? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Ascendis Pharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.52) | Revenue Per Share | Quarterly Revenue Growth 2.694 | Return On Assets | Return On Equity |
Understanding Ascendis Pharma AS requires distinguishing between market price and book value, where the latter reflects Ascendis's accounting equity. The concept of intrinsic value - what Ascendis Pharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Ascendis Pharma's price substantially above or below its fundamental value.
Understanding that Ascendis Pharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Ascendis Pharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Ascendis Pharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.